NIH awards $75 million to establish medical research consortium to combat health disparities

December 17, 2015

Revenue for the nine months ended September 30, 2009 totaled $988.0 million compared to $1,035.3 million for the comparable period a year ago. Excluding the elimination of CAP and UHG, the year-to-date 2009 revenue grew 7.4% over the comparable period in 2008.

Gross profit for the nine months ended September 30, 2009 was $115.9 million, or 11.7% compared to $104.2 million, or 10.1% for the same period in 2008. The increase in gross margin for the year was the result of improved product and therapy mix, the elimination of lower margin business and improved supply chain programs.

Operating profit for the nine months ended September 30, 2009 was $16.1 million, or 1.6% compared to $6.4 million, or 0.6% for the comparable period of 2008. Net income for the nine months ended 2009 was $13.4 million, or $0.34 per diluted share, compared to $2.6 million, or $0.07 per diluted share, for the same period one year ago.

The Company also announced that Steven Schelhammer has resigned as a member of the company's Board of Directors in order to devote his full-time attention to his position as Chief Executive Officer of Phytel, Inc. ???On behalf of the entire Board of Directors, we thank Steve for his important contributions to BioScrip,??? stated Friedman.

SOURCE BioScrip, Inc.